700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
Diabetes mellitus is a worldwide health problem, which is a chronic metabolic disorder leads to defect in insulin secretion also causes restriction in metabolism of fats, carbohydrates and protein metabolism. The most effective anti-diabetic drugs currently available include insulin and sulphonylureas, biguanides, meglitinides, thiazolidinediones, alpha- glucosidase inhibitors, incretins, DPP-4 inhibitors, Amylin analogs. Worldwide 382 million people will have Diabetes mellitus. As the disease in severe conditions causes diabetic complications such as retinopathy, neuropathy, nephropathy, cardiovascular complications and ulceration. Diabetes mellitus is of several types among them type-1 and type-2 are major types. Type-2 DM is an incomplete understood chronic disease. It is noninsulin dependent Diabetes mellitus or adult-onset diabetes. it is characterized by hyperglycemia, means lack of insulin. The symptoms include excess thirst, frequent urination, and constant hunger. Type-2 Diabetes mellitus are about 90% cases of diabetes, other 10% belongs to type-1 and gestational diabetes. Currently available therapies for type II diabetes mellitus are as follows oral insulin secretagogues, sulfonylureas, repaglinide, nateglinide, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, insulin, pramlintide and exenatide. The aim of diabetes treatment is to secure a quality of life and lifespan comparable to those of healthy people and a prerequisite for this is the prevention of onset and progression of vascular complications. The need for earlier initiation of proactive intervention must be emphasized, as well as the importance of comprehensive (blood sugar, blood pressure, and lipids) intervention in attaining this goal.
To read the full article Peer-reviewed Article PDF
Author(s): T. Pradeep, C. Haranath
Dipeptidyl peptidase-4, insulin, peptide analogues, type 2 diabetes, Diabetes Research and Clinical Practice,Diabetes Research and Clinical Practice